Q-omics provides the consensus-scored CLCN6 profile across patient tissues and cancer cell-line models. CLCN6 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CLCN6 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, CLCN6 protein abundance shows 21,212 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, HNSC, and GBM as cancer lineages where CLCN6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CLCN6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CLCN6 survival associations across molecular data types. CLCN6 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CLCN6 RNA expression–survival associations across cancer types. High CLCN6 expression shows unfavorable associations in ACC, LUSC, LIHC and KICH, but favorable associations in KIRC and LUAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CLCN6 RNA expression.
This table summarizes CLCN6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for CLCN6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CLCN6 shows lower tumor expression in THCA, LUAD, BRCA and LUSC and higher tumor expression in HNSC and LIHC. The HNSC box plot shows higher CLCN6 RNA expression in tumor versus normal tissue (log2 FC = +0.518, t-test p < 0.001).
This table shows molecular features associated with CLCN6 in patient tissues and cancer cell lines. In patient samples, CLCN6 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CLCN6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Lymphoma.
